Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
Esperion Therapeutics, Inc. (ESPR)
Last esperion therapeutics, inc. earnings: 2/27 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.esperion.com
Company Research
Source: GlobeNewswire
– Reports $156 to $160 Million in Preliminary* Full-Year 2025 U.S. Net Product Sales, a 35% to 38% Increase Compared With Full-Year 2024 – –Total Preliminary* Revenue of $400 to $408 million, a 20% to 23% Increase Compared With Full-Year 2024, and ~55% to 59% Increase Excluding One-Time Milestones – – Cash and Cash Equivalents of Approximately $168 Million* at Year-End 2025 – – Q4 Retail Prescription Equivalents Grew 34% Y/Y and 11.3% Q/Q – – Expects Operating Expenses of Between $210 Million and $245 Million for Full-Year 2026 – – Introduces Vision 2040 Growth Strategy Focused on Global Growth of Cardiometabolic Franchise and Expansion of Pipeline into Rare Hepatic and Renal Diseases – ANN ARBOR, Mich., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today provides preliminary financial results for the full-year 2025, including U.S. net product sales, cash and cash equivalents and expectations for 2026 operating expenses. “2025 marked the most successful yea
Show less
Read more
Impact Snapshot
Event Time:
ESPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ESPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ESPR alerts
High impacting Esperion Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ESPR
News
- Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Esperion Therapeutics (NASDAQ:ESPR) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ESPR&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StrMarketBeat
- Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With DiabetesGlobeNewswire
- Why The Narrative Around Esperion Therapeutics Is Shifting After Analyst Upgrades And Trial Results [Yahoo! Finance]Yahoo! Finance
ESPR
Earnings
- 11/6/25 - Miss
ESPR
Sec Filings
- 1/12/26 - Form 8-K
- 12/18/25 - Form 4
- 12/18/25 - Form 4
- ESPR's page on the SEC website